Metformin mitigates insulin signaling variations induced by COVID-19 vaccine boosters in type 2 diabetes

Lixiang Zhai,Min Zhuang,Hoi Ki Wong,Chengyuan Lin,Jialing Zhang,Gengyu Bao,Yijing Zhang,Shujun Xu,Jingyuan Luo,Shuofeng Yuan,Hoi Leong Xavier Wong,Zhao-xiang Bian

DOI: https://doi.org/10.1101/2023.12.27.23299358

2024-01-02

Abstract:Diabetes is associated with an increased risk of Coronavirus disease 2019 (COVID-19) vulnerability and mortality. COVID-19 vaccines significantly reduce the risks of serious COVID-19 outcomes, but the impact of COVID-19 vaccines including their effectiveness and adverse effects in patients with diabetes are not well known yet. Here, we showed that 61.1% patients with type 2 diabetes, but not healthy controls, exhibited aggravated insulin resistance towards the booster shots of the COVID-19 vaccine. Furthermore, we showed that COVID-19 vaccination once a week also impaired insulin sensitivity in healthy mice after four weeks. We further showed that metformin, a common anti-diabetic medication, improved the impaired insulin signaling induced by COVID-19 vaccination in mice. This study suggests clinical implications for the close monitoring of glycemic control in diabetic patients after receiving COVID-19 vaccines and indicates the beneficial action of metformin in counteracting insulin signaling variations induced by COVID-19 vaccination in diabetic patients.

Endocrinology (including Diabetes Mellitus and Metabolic Disease)

What problem does this paper attempt to address?

The paper primarily explores the impact of COVID-19 vaccine boosters on insulin signaling and blood glucose control in vaccinated individuals, and investigates the potential mitigating role of metformin in this process.

Specifically, the study found that COVID-19 vaccine boosters may lead to exacerbated insulin resistance in patients with type 2 diabetes. In clinical trials, approximately 61.1% of type 2 diabetes patients exhibited a decrease in insulin sensitivity after receiving the booster shot. Additionally, similar phenomena were observed in healthy mouse models: regular COVID-19 vaccination led to reduced glucose tolerance and impaired insulin sensitivity in mice. The study further revealed that the SARS-CoV-2 spike protein might cause these adverse reactions by affecting the insulin signaling pathway.

Notably, the research also indicated that metformin could significantly improve the insulin resistance observed after COVID-19 vaccination, including restoring impaired insulin signaling in mouse models, without affecting the protective efficacy of the vaccine itself.

In summary, this paper aims to address the following key issues:
1. **The impact of COVID-19 vaccine boosters on insulin signaling in diabetic patients**: The study shows that boosters may exacerbate insulin resistance in diabetic patients.
2. **The mitigating role of metformin on insulin resistance induced by COVID-19 vaccine boosters**: Metformin has been shown to alleviate this adverse reaction.
3. **The mechanism of action of the SARS-CoV-2 spike protein**: The spike protein may interfere with the insulin signaling pathway through specific mechanisms, thereby affecting blood glucose control.